Informace o publikaci

Cost-effectiveness of Tyrosine Kinase Inhibitor Treatment Strategies for Chronic Myeloid Leukemia in Chronic Phase After Generic Entry of Imatinib in the United States

Autoři	PADULA William V. LARSON Richard A. DUSETZINA Stacie B. APPERLEY Jane F. HEHLMANN Rudiger BACCARANI Michele EIGENDORFF Ekkehard GUILHOT Joelle GUILHOT Francois HEHLMANN Rudiger MAHON Francois-Xavier MARTINELLI Giovanni MAYER Jiří MÜLLER Martin C. NIEDERWIESER Dietger SAUSSELE Susanne SCHIFFER Charles A. SILVER Richard T. SIMONSSON Bengt CONTI Rena M.
Rok publikování	2016
Druh	Článek v odborném periodiku
Časopis / Zdroj	Journal of the National Cancer Institute
Fakulta / Pracoviště MU	Lékařská fakulta
Citace
Doi	http://dx.doi.org/10.1093/jnci/djw003
Obor	Onkologie a hematologie
Klíčová slova	CHRONIC MYELOGENOUS LEUKEMIA; EARLY MOLECULAR RESPONSE; FOLLOW-UP; ECONOMIC-BENEFITS; PRICE-COMPETITION; THERAPY; DASATINIB; INTERFERON; NILOTINIB; OUTCOMES
Přiložené soubory	EL_1342298.pdf
Popis	Background: We analyzed the cost-effectiveness of treating incident chronic myeloid leukemia in chronic phase (CML-CP) with generic imatinib when it becomes available in United States in 2016. In the year following generic entry, imatinibs price is expected to drop 70% to 90%. We hypothesized that initiating treatment with generic imatinib in these patients and then switching to the other tyrosine-kinase inhibitors (TKIs), dasatinib or nilotinib, because of intolerance or lack of effectiveness (“imatinib-first”) would be cost-effective compared with the current standard of care: “physicians choice” of initiating treatment with any one of the three TKIs. Methods: We constructed Markov models to compare the five-year cost-effectiveness of imatinib-first vs physician’s choice from a US commercial payer perspective, assuming 3% annual discounting ($US 2013). The models clinical endpoint was five-year overall survival taken from a systematic review of clinical trial results. Per-person spending on incident CML-CP treatment overall care components was estimated using Truven’s MarketScan claims data. The main outcome of the models was cost per quality-adjusted life-year (QALY). We interpreted outcomes based on a willingness-to-pay threshold of $100 000/QALY. A panel of European LeukemiaNet experts oversaw the studys conduct. Results: Both strategies met the threshold. Imatinib-first ($277 401, 3.87 QALYs) offered patients a 0.10 decrement in QALYs at a savings of $88 343 over five years to payers compared with physician’s choice ($365 744, 3.97 QALYs). The imatinibfirst incremental cost-effectiveness ratio was approximately $883 730/QALY. The results were robust to multiple sensitivity analyses. Conclusion: When imatinib loses patent protection and its price declines, its use will be the cost-effective initial treatment strategy for CML-CP.